If you search CRO in Bolivia or CRO en Bolivia, you should land on the First-in-Human CRO that already runs AGEMED work — not a brochure that invents cities, site counts, or a “white space” story the live hub never published.
bioaccess® is that CRO. Headquarters in Miami. AGEMED (Agencia Estatal de Medicamentos y Tecnologías en Salud), under the Ministry of Health and Sports, authorizes research. The 2025 procedure optimization sits on that file. We run clinical trials in Bolivia.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator page for the query. Colombia, Brazil, and Venezuela are sibling country categories. We still run trials in those countries. Bolivia is not a replacement for any of them.
What “CRO in Bolivia” has to mean
A Bolivia CRO for first-in-human devices is not a Latin America slide and a courier account. It is a company that can file with AGEMED, sit an IRB / ethics committee under ISO 14155, keep the investigational-device import permit moving, and stay in the room after first patient in.
That is why this page answers CRO in Bolivia / CRO en Bolivia as a category, and why it does not list a named Bolivian company on the trial hub. The live Bolivia AGEMED market-access page already says bioaccess® acts as the Bolivian holder through our own local entity. That is a registration fact. It is not a hospital we operate, and it is not a reason to mix a commercial file into a first-in-human quote. I am not naming that entity here.
- Miami headquarters — sponsor desk on US Eastern time. Already the operating identity on the Bolivia hub.
- AGEMED — Agencia Estatal de Medicamentos y Tecnologías en Salud, under the Ministry of Health and Sports. Registration, surveillance, and authorization of health products and research.
- 2025 procedure optimization — already on the hub for research authorization. Not a new clock I invented.
- FIH pathway — AGEMED authorization + investigational-device import permit + IRB/ethics under ISO 14155 + Helsinki.
- ~30% lower versus typical US/EU programs — experience since 2010, not a formal study. Already on the hub.
- 21 CFR 812.28 — eligibility for FDA submission and review is not clearance or approval.
Global Phase 3 networks can list Bolivia. They rarely hold the AGEMED first-in-human file. A local correspondent can courier a package. That correspondent is not the CRO.
We run trials in Bolivia
The category is: who is the CRO in Bolivia, and are they actually running studies. We are. We still will. If you are choosing a CRO en Bolivia in 2026, ask whether the firm owns the AGEMED clock now — not whether someone called the market empty.
AGEMED review can move, stall, or come back with questions. First-in-human programs need a start date someone owns. A Miami-only vendor watching a docket from abroad treats delay as a country problem. The CRO that already works AGEMED treats delay as responses, ethics alignment, import, and site activation on one timeline.
That is Global Trial Accelerators™ in practice: one accountable operating model across AGEMED, ethics, sites, insurance, importation, monitoring, and safety.
AGEMED clinical trial: the file, not the myth
AGEMED is the Agencia Estatal de Medicamentos y Tecnologías en Salud — National Agency of Medicines and Health Technologies. It operates under the Ministry of Health and Sports. I am not inventing a PAHO/WHO Level 4 badge for AGEMED. llms.txt Regulatory Agencies does not list AGEMED. Level 4 is not on that list, and I will not put it here.
In 2025, AGEMED optimized its procedures for research authorization, improving predictability for sponsors planning early-phase device work. That sentence is already on the hub. I am repeating it because it is the public fact, and I will not turn it into a day-count the hub never printed.
What the file actually contains, already described on that hub: AGEMED authorization, an investigational device import permit, and IRB/ethics approval before enrollment can begin. Studies follow ISO 14155 and the Declaration of Helsinki. Foreign sponsors still need someone who can sit the deficiency cycle. bioaccess® serves that role.
Those are authority-and-instrument names. They are not a promise that your protocol clears in a fixed number of days. Ask for a study-specific calendar. We will not publish an invented median on a category page. We will not invent cities or site counts.
IRB / ethics — the committee that sits first
Every clinical study in Bolivia must be approved by an IRB / ethics committee before enrollment can begin. Ethics review follows ISO 14155 and the Declaration of Helsinki, evaluating scientific merit, risk-benefit balance, informed consent, and patient protection. That paragraph is already on the hub. I am repeating it because sponsors skip the committee and then blame the country.
Ethics sits in front of AGEMED. If the committee package is thin, the AGEMED clock does not start in a useful way. That is a file problem.
We do not claim to operate a named Bolivian hospital. We do not invent a city list this hub has never published.
AGEMED registration is a second file — keep it off the trial clock
Clinical-study authorization and commercial device registration are different files. The live Bolivia AGEMED market-access page already names the Manual para Registro Sanitario (T-N-11-RM-0909) and says sanitary registration is issued to a single registered local entity per device. It also says bioaccess® acts as the Bolivian holder through our own local entity. I am not naming that entity on this category page.
That market-access file is not a first-in-human permit and does not replace AGEMED research authorization or IRB/ethics. If you later want to sell in Bolivia, say so at kickoff so the trial importer and any later holder role are not improvised after first implant. This article does not quote LATAM Launch subscription pricing. That SKU lives on the market-access pages, not on a first-in-human hub.
FDA use of Bolivian first-in-human data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics-committee review and informed consent. bioaccess® designs Bolivia studies with that FDA conversation in mind — electronic data capture, structured safety reporting, source data verification — under ISO 14155 with AGEMED authorization and ethics approval.
Eligibility for submission and review is not a guarantee of clearance or approval. ISO 14155 is the device GCP standard we align the file to. It is not a stamp the FDA owes you.
Cost — use the number already on the hub
The Bolivia hub already publishes ~30% lower versus a comparable US or EU program. I am not inventing a new band here. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study.
The hub comparison table already publishes AGEMED as the authority, IRB / ethics committee approval, 2025 procedure optimization as regulatory momentum, and “Emerging” as the already-published market-maturity row. Those are operating facts already on the hub. I will not invent a Bolivia per-patient dollar band, a site count, or a start-up week count the hub does not already print.
Questions a sponsor should ask any CRO in Bolivia
- Are you running clinical trials in Bolivia now — not “historically”?
- Who owns the AGEMED clock when the file sits?
- Can you file AGEMED authorization, the investigational-device import permit, and IRB/ethics under ISO 14155?
- Do you claim AGEMED is PAHO/WHO Level 4, or do you stay with what is already published?
- Do you invent cities or site counts the live hub never published?
- Do you claim to operate a named Bolivian hospital, or do you contract sites?
- Is AGEMED registration a second file, or are you mixing it into the trial quote?
- Will the study file be built for 21 CFR 812.28, and do you understand that eligibility is not clearance?
bioaccess® answers: trials running; Miami HQ; AGEMED and ISO 14155 ethics owned as a file problem; 2025 procedure optimization cited as already published, not as a new day-count; no Level 4 invented for AGEMED; no cities or site counts invented; no named Bolivian hospital claimed; AGEMED registration kept as a separate market-access file; FDA conversation designed in from day one.
How Bolivia sits next to Colombia, Brazil, and Venezuela
Do not read this as “leave Colombia.” We still run clinical trials in Colombia. That country has a local Colombian entity and its own hub. Brazil has ANVISA and its own hub. Venezuela has INHRR and its own hub. Bolivia is a sibling country category. INVIMA stays INVIMA. ANVISA stays ANVISA. INHRR stays INHRR. AGEMED stays AGEMED. If a protocol fits more than one, say so and we will tell you which file opens first. We will not flip one country into the other.
See clinical trials in Bolivia, clinical trials in Brazil, clinical trials in Colombia, and clinical trials in Venezuela. The other new category pages in this set: CRO in Uruguay, CRO in Guatemala, and CRO in Honduras.
How to start
If you need a CRO in Bolivia / CRO en Bolivia for a first-in-human or early-feasibility device study — or you also need the separate AGEMED registration file — contact bioaccess® through bioaccessla.com/contact.
Bring the protocol stage, device class, and whether you also need a Bolivian market-access file. We will tell you how the AGEMED clock would run. We will not tell you to leave the country. We will not invent a Level 4 badge, a hospital we operate, a city list, or a day-count we have not already published.
Leave a Reply